Correction to “Nivolumab Plus Chemotherapy or Ipilimumab Versus Chemotherapy in Patients With Advanced Esophageal Squamous Cell Carcinoma ( CheckMate 648): 29‐Month Follow‐Up From a Randomized, Open‐Label, Phase III Trial”

Documents similaires

• Organ‐Specific Responses to Nivolumab Plus Ipilimumab in Advanced Hepatocellular Carcinoma: A Multicenter, Retrospective Study
  par: Jung Sun Kim, et autres
  Publié: (2025)
• Nivolumab plus chemotherapy or ipilimumab versus chemotherapy in patients with advanced esophageal squamous cell carcinoma (CheckMate 648): 29‐month follow‐up from a randomized, open‐label, phase III trial
  par: Ken Kato, et autres
  Publié: (2024)
• Impacts of Mitochondrial Status After Neoadjuvant Chemotherapy in Esophageal Squamous Cell Carcinoma Patients
  par: Kotaro Sugawara, et autres
  Publié: (2025)
• Clinical Implications of Nutritional Intake in Patients With Esophageal Squamous Cell Carcinoma Receiving Chemoradiotherapy and Neoadjuvant Chemotherapy
  par: Yumiko Tamai, et autres
  Publié: (2026)
• Administration of nivolumab plus ipilimumab: Infusion of the fixed‐ratio combination versus sequential infusions in two randomized controlled trials of metastatic melanoma (CheckMate 742) and renal cell carcinoma (CheckMate 800)
  par: Alexander M. Menzies, et autres
  Publié: (2025)